Press coverage about Lantheus (NASDAQ:LNTH) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lantheus earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.7983815594762 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Lantheus (LNTH) Lowered to Hold at ValuEngine (americanbankingnews.com)
- Head to Head Review: Lantheus (LNTH) and Its Peers (americanbankingnews.com)
- Lantheus (LNTH) Upgraded to Outperform at Wells Fargo (americanbankingnews.com)
- Lantheus (LNTH) Upgraded to Strong-Buy by Zacks Investment Research (americanbankingnews.com)
- Zacks Investment Research Lowers Lantheus (LNTH) to Hold (americanbankingnews.com)
Lantheus stock opened at $15.90 on Thursday. The stock has a market capitalization of $601.98, a PE ratio of 15.90, a PEG ratio of 1.27 and a beta of 1.52. The company has a debt-to-equity ratio of 11.40, a current ratio of 3.16 and a quick ratio of 2.60. Lantheus has a 12-month low of $10.65 and a 12-month high of $24.45.
LNTH has been the subject of several analyst reports. Zacks Investment Research lowered shares of Lantheus from a “hold” rating to a “strong sell” rating in a report on Friday, March 2nd. BidaskClub upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. TheStreet upgraded shares of Lantheus from a “d” rating to a “c-” rating in a report on Monday, March 19th. Finally, ValuEngine upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, February 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Lantheus presently has an average rating of “Hold” and a consensus price target of $24.75.
In related news, insider Michael P. Duffy sold 11,492 shares of the firm’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $16.60, for a total value of $190,767.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Timothy G. Healey sold 3,696 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $19.58, for a total transaction of $72,367.68. Following the completion of the transaction, the senior vice president now directly owns 64,582 shares in the company, valued at approximately $1,264,515.56. The disclosure for this sale can be found here. Insiders sold a total of 40,709 shares of company stock worth $839,135 in the last ninety days. 1.20% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Lantheus (NASDAQ:LNTH) Receiving Somewhat Positive Media Coverage, Analysis Shows” was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/2018/04/05/lantheus-lnth-getting-somewhat-favorable-press-coverage-accern-reports/2024289.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.